WO2006010805A3 - Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila - Google Patents

Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila Download PDF

Info

Publication number
WO2006010805A3
WO2006010805A3 PCT/FR2005/001548 FR2005001548W WO2006010805A3 WO 2006010805 A3 WO2006010805 A3 WO 2006010805A3 FR 2005001548 W FR2005001548 W FR 2005001548W WO 2006010805 A3 WO2006010805 A3 WO 2006010805A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitro
legionella pneumophila
isolating
polynucleotides
novel polypeptides
Prior art date
Application number
PCT/FR2005/001548
Other languages
English (en)
Other versions
WO2006010805A2 (fr
Inventor
Jean-Philippe Arie
Camille Cyncynatus
Original Assignee
Abag Sa
Univ Claude Bernard Lyon
Jean-Philippe Arie
Camille Cyncynatus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0407114A external-priority patent/FR2872289B1/fr
Priority claimed from FR0408714A external-priority patent/FR2874025B1/fr
Priority claimed from FR0413063A external-priority patent/FR2878861B1/fr
Application filed by Abag Sa, Univ Claude Bernard Lyon, Jean-Philippe Arie, Camille Cyncynatus filed Critical Abag Sa
Priority to AT05778861T priority Critical patent/ATE441865T1/de
Priority to DE602005016417T priority patent/DE602005016417D1/de
Priority to EP05778861A priority patent/EP1769249B1/fr
Publication of WO2006010805A2 publication Critical patent/WO2006010805A2/fr
Publication of WO2006010805A3 publication Critical patent/WO2006010805A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet de nouveaux polynucléotides, comprenant la séquence ID SEQ N°1 ou des parties ou des variants de ladite séquence, de nouveaux polypeptides codés par ces polynucléotides, des vecteurs d'expression comprenant lesdits polynucléotides et des cellules hôtes comprenant lesdits vecteurs d'expression. Ces polynucléotides et ces polypeptides sont utilisables dans le domaine du diagnostic in vitro et/ou la production de vaccins contre . Legionella pneumophila.
PCT/FR2005/001548 2004-06-29 2005-06-21 Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila WO2006010805A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT05778861T ATE441865T1 (de) 2004-06-29 2005-06-21 Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
DE602005016417T DE602005016417D1 (de) 2004-06-29 2005-06-21 Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
EP05778861A EP1769249B1 (fr) 2004-06-29 2005-06-21 Nouveaux polypeptides pour la mise en évidence in vitro et la prévention des infections à legionella pneumophila

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR0407114 2004-06-29
FR0407114A FR2872289B1 (fr) 2004-06-29 2004-06-29 Utilisation de la proteine g5 dans le diagnostic in vitro d'infection a legionella pneumophila
FR0408714A FR2874025B1 (fr) 2004-08-06 2004-08-06 Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila
FR0408714 2004-08-06
FR0413063A FR2878861B1 (fr) 2004-12-08 2004-12-08 Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila
FR0413063 2004-12-08

Publications (2)

Publication Number Publication Date
WO2006010805A2 WO2006010805A2 (fr) 2006-02-02
WO2006010805A3 true WO2006010805A3 (fr) 2006-06-22

Family

ID=35169467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001548 WO2006010805A2 (fr) 2004-06-29 2005-06-21 Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila

Country Status (4)

Country Link
EP (1) EP1769249B1 (fr)
AT (1) ATE441865T1 (fr)
DE (1) DE602005016417D1 (fr)
WO (1) WO2006010805A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2895519B1 (fr) * 2005-12-28 2008-12-19 Abag Sa Utilisation de la proteine 5e2 dans le diagnostic in vitro d'infection a legionella pneumophila
FR2930646B1 (fr) * 2008-04-29 2012-09-07 Abag Detection, in vitro, d'anticorps produits a la suite d'une infection a legionella pneumophila
US8785145B2 (en) 2011-08-11 2014-07-22 Ingen Biosciences Method for diagnosing gram-negative infections
EP2586789A1 (fr) * 2011-08-11 2013-05-01 InGen Biosciences Procédé pour le diagnostic d'infections Gram-négatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006469A1 (fr) * 1986-04-25 1987-11-05 Technology Licence Company Limited Anticorps monoclonaux et leur utilisation
WO1999064610A1 (fr) * 1998-06-11 1999-12-16 St. Jude Children's Research Hospital Zmpb, nouveau determinant de la virulence de streptococcus pneumoniae, vaccin obtenu a partir de celui-ci et utilisations de ceux-ci

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006469A1 (fr) * 1986-04-25 1987-11-05 Technology Licence Company Limited Anticorps monoclonaux et leur utilisation
WO1999064610A1 (fr) * 1998-06-11 1999-12-16 St. Jude Children's Research Hospital Zmpb, nouveau determinant de la virulence de streptococcus pneumoniae, vaccin obtenu a partir de celui-ci et utilisations de ceux-ci

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BANGSBORG JETTE M ET AL: "Performance of four different indirect enzyme-linked immunosorbent assays (ELISAs) to detect specific IgG, IgA, and IgM in Legionnaires' disease", APMIS, vol. 102, no. 7, 1994, pages 501 - 508, XP008055172, ISSN: 0903-4641 *
BLACK W J ET AL: "Legionella pneumophila zinc metalloprotease is structurally and functionally homologous to Pseudomonas aeruginosa elastase.", JOURNAL OF BACTERIOLOGY. MAY 1990, vol. 172, no. 5, May 1990 (1990-05-01), pages 2608 - 2613, XP002318264, ISSN: 0021-9193 *
MALAN A K ET AL: "Comparison of two commercial enzyme-linked immunosorbent assays with an immunofluorescence assay for detection of Legionella pneumophila types 1 to 6", JOURNAL OF CLINICAL MICROBIOLOGY 01 JUL 2003 UNITED STATES, vol. 41, no. 7, 1 July 2003 (2003-07-01), pages 3060 - 3063, XP002318266, ISSN: 0095-1137 *
MCINTYRE M ET AL: "RAPID IDENTIFICATION OF LEGIONELLA-PNEUMOPHILA ZINC METALLOPROTEASE USING CHROMOGENIC DETECTION", APMIS, vol. 99, no. 4, 1991, pages 316 - 320, XP008043164, ISSN: 0903-4641 *
MOFFAT JENNIFER F ET AL: "Further molecular characterization of the cloned Legionella pneumophila zinc metalloprotease", INFECTION AND IMMUNITY, vol. 62, no. 2, 1994, pages 751 - 753, XP002318265, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
EP1769249B1 (fr) 2009-09-02
ATE441865T1 (de) 2009-09-15
EP1769249A2 (fr) 2007-04-04
DE602005016417D1 (de) 2009-10-15
WO2006010805A2 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2008140812A3 (fr) Compositions et procédés comprenant des antigènes klk3, psca ou folh1
WO2003025148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002070539A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002081731A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2005121331A3 (fr) Polypeptides galnact2 tronques et acides nucleiques
EP2298872A3 (fr) Polypeptides dotés d'activité lipase et polynucléotides les codant
WO2007051164A3 (fr) Modulateurs du recepteur de type toll 3, et leurs procedes et utilisations
WO2003029271A3 (fr) Nouveaux acides nucleiques et polypeptides
EP1889907A4 (fr) Nouvelle transférase de groupe aminé, gène codant celle-ci et procédé d'utilisation de celle-ci
WO2008104979A3 (fr) Séquences de ciblage du noyau
WO2008112258A3 (fr) Protéases modifiées
WO2008086035A3 (fr) Rapporteur de fusion d'hydrolase mutante divisée et utilisations de celui-ci
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
WO2008087224A3 (fr) Netrine 4 mutée, fragments de cette dernière et utilisations comme médicament
WO2008113536A8 (fr) Peptides neurotrophiques
WO2006063028A3 (fr) Compositions immunostimulantes et utilisations de celles-ci
WO2006010805A3 (fr) Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila
WO2008047370A3 (fr) Compositions et méthodes permettant d'induire l'angiogenèse
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2008148932A3 (fr) Procédé pour le traitement de cancers ou de maladies inflammatoires
WO2007069249A3 (fr) Polypeptides de type toxine, polynucleotides codant pour ceux-ci et utilisations de ceux-ci
WO2006053565A3 (fr) Polypeptides antimicrobiens et polynucleotides les codant
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005778861

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005778861

Country of ref document: EP